Rep. Schrader Issues Statement Following FDA's Budget Request Includes His Proposal To Close Loophole in Generic Drug Approval Process
March 30, 2022
March 30, 2022
WASHINGTON, March 30 -- Rep. Kurt Schrader, D-Oregon, issued the following news release:
U.S. Congressman Kurt Schrader (OR-05) issued the following statement in response to the FDA's budget request for the President's FY23 budget that includes a proposal to amend the process for beginning the clock on the 180-day exclusivity period for being the first generic to market to encourage timely entry of third and fourth competitor, generic drugs:
"I am pleased to see th . . .
U.S. Congressman Kurt Schrader (OR-05) issued the following statement in response to the FDA's budget request for the President's FY23 budget that includes a proposal to amend the process for beginning the clock on the 180-day exclusivity period for being the first generic to market to encourage timely entry of third and fourth competitor, generic drugs:
"I am pleased to see th . . .